January 30, 2017. After a seven-day bench trial in October and November 2016, Judge Gregory M. Sleet of the U.S. District Court for the District of Delaware issued a post-trial opinion in a consolidated Hatch-Waxman patent infringement action concerning generic versions of COPAXONE® 40mg, finding the patents-in-suit invalid for obviousness under 35 U.S.C. § 103. Neal Belgam and Eve Ormerod represented defendants Synthon Pharmaceuticals Inc., Synthon B.V., Synthon s.r.o. Blansko, and Pfizer Inc.